Cost-effectiveness of PET imaging in clinical oncology☆
References (23)
- et al.
Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules
Chest
(1993) - et al.
Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG)
Gynecol. Oncol.
(1993) - et al.
Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer
Lancet
(1994) - et al.
Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucose
Ann. Thorac. Surg.
(1994) - et al.
Staging non-small-cell lung cancer by whole-body positron emission tomographic imaging
Ann. Thorac. Surg.
(1995) - et al.
Evaluation of breast masses and axillary lymph nodes with [18F]2-deoxy-2-fluoro-d-glucose PET
Radiology
(1993) - et al.
Positron emission tomography and breast masses: Comparison with clinical, mammographic and pathological findings
Ann. Surg. Oncol.
(1994) - et al.
Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-d-glucose in the imaging of malignant melanoma
J. Nucl. Med.
(1993) - et al.
Recurrent rectal cancer and scar: Differentiation with PET and MR imaging
Radiology
(1992) - et al.
The importance of whole-body PET scans in the management of metastatic malignant melanoma
Imaging of lymphoma with PET with 2-[18]-fluoro-2-deoxy-glucose: Correlation with CT
Radiology
(1994)
Cited by (0)
- ☆
This work was supported by a grant from the Sutter Institute for Medical Research, Sacramento, CA.
Copyright © 1996 Published by Elsevier Inc.